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Abstract 
Motivation: Genome-wide association studies have identified thousands of loci associated with hu-
man disease, but identifying the causal genes at these loci is often difficult. Several methods prioritise 
genes most likely to be disease causing through the integration of biological data, including protein-
protein interaction and phenotypic data. Data availability is not the same for all genes however, po-
tentially influencing the performance of these methods. 
Results: We demonstrate that whilst disease genes tend to be associated with greater numbers of 
data, this may be at least partially a result of them being better studied. With this observation we de-
velop PhenoRank, which prioritises disease genes whilst avoiding being biased towards genes with 
more available data. Bias is avoided by comparing gene scores generated for the query disease 
against gene scores generated using simulated sets of phenotype terms, which ensures that differ-
ences in data availability do not affect the ranking of genes. We demonstrate that whilst existing prior-
itisation methods are biased by data availability, PhenoRank is not similarly biased. Avoiding this bias 
allows PhenoRank to effectively prioritise genes with fewer available data and improves its overall 
performance. PhenoRank outperforms three available prioritisation methods in cross-validation (Phe-
noRank area under receiver operating characteristic curve [AUC]=0.89, DADA AUC=0.87, 
EXOMISER AUC=0.71, PRINCE AUC=0.83, P < 2.2 × 10-16). 
Availability: PhenoRank is freely available for download at 
https://github.com/alexjcornish/PhenoRank. 
Contact: m.sternberg@imperial.ac.uk. 
Supplementary information: Supplementary data are available at Bioinformatics online. 
 
1 Introduction  
Genome-wide association studies (GWAS) have identified thousands of 
genomic variants associated with a range of human traits, including 
susceptibilities to many diseases. Disease-associated variants are them-
selves rarely causal and instead ‘tag’ regions of the genome containing 
variants in linkage disequilibrium, any one of which may be the causal 
variant. These causal variants may be located in the coding region of a 
gene, or in a regulatory region and disrupt the expression of a gene 
through cis or trans-acting regulatory mechanisms (Jäger et al., 2015), 
making the identification of causal genes often difficult. This has led to 
the development of methods that integrate biological data to prioritise 
likely causal genes (Köhler et al., 2008; Vanunu et al., 2010; Erten et al., 
2011; Yates et al., 2014; Smedley et al., 2015). 
Network-based methods have been demonstrated to be effective at 
prioritising disease-causing genes (Köhler et al., 2008; Vanunu et al., 
2010; Erten et al., 2011; Yates et al., 2014; Smedley et al., 2015; Cowen 
et al., 2017). These approaches often score genes more highly if they, or 
their protein products, interact with genes known to be associated with 
the query disease, or genes associated with diseases that are phenotypi-
cally similar to the query disease (Vanunu et al., 2010; Erten et al., 2011; 
Smedley et al., 2015). Yates et al. found that disease proteins tend to 
occupy more central positions in PPI networks than non-disease proteins 
(Yates and Sternberg, 2013), whilst Das et al. found this to be true, but 
only for PPI networks generated through literature-curation (Das and Yu, 
2012). Some network-based methods therefore score genes and gene 
variants whose protein products are more central in PPI networks higher 
than those that are less central (Fu et al., 2014; Yates et al., 2014). The 
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centrality measures used by these methods are correlated with the num-
ber of interactions a protein is involved in (Valente et al., 2008). It has 
been suggested however that some proteins may be involved in more 
interactions in literature-curated PPI networks as a result of them being 
better studied (Das and Yu, 2012; Gillis and Pavlidis, 2012). If this is 
true, then network-based methods that score genes central in a network 
more highly may be less effective at prioritising genes that are less well 
studied, as these genes may be more peripheral in a network, as a result 
of them having fewer available data.  
Databases such as ClinVar (Landrum et al., 2016), OMIM 
(Amberger et al., 2015) and UniProtKB (The UniProt Consortium, 2014) 
collate data on the relationships between genetic variation and human 
disease. Databases that associate genetic variation with phenotypic ab-
normalities have also been established for model organisms (Bult et al., 
2016) and used to study human disease (Chen et al., 2012; Smedley et 
al., 2015). It has been demonstrated that disease genes can be prioritised 
by identifying genes implicated in phenotypically similar diseases 
(Vanunu et al., 2010; Smedley et al., 2015). For example, novel causal 
genes for prostate cancer may be inferred by identifying genes implicat-
ed in other cancers (Vanunu et al., 2010). Similarly, candidate disease 
genes in humans can be prioritised by identifying orthologous mouse 
genes whose mutation causes similar phenotypes in mice (Chen et al., 
2012; Smedley et al., 2015).  
Multiple approaches have been proposed to quantify the phenotypic 
similarity of human diseases. Phenotype ontologies, such as the Human 
Phenotype Ontology (HPO) (Köhler et al., 2014) and the Mammalian 
Phenotype Ontology (MP) (Smith, Goldsmith and Eppig, 2005), provide 
standardized and structured vocabularies of observed phenotypic abnor-
malities. Multiple phenotype ontology terms can be mapped to a human 
disease to describe the phenotypic features of the disease. These features 
can include abnormalities associated with the disease (for example ‘Ab-
normality of the outer ear’), its mode of inheritance (for example ‘Auto-
somal dominant inheritance’) and clinical features (for example ‘Child-
hood onset’). The structured nature of ontologies allows the similarity of 
terms to be quantified. For example, the HPO terms ‘IgM deficiency’ 
and ‘IgE deficiency’ are both subclasses of ‘Decreased antibody level in 
blood’ and may therefore be considered similar. The HPO terms ‘IgM 
deficiency’ and ‘Dementia’ are less well connected in the ontology and 
may therefore be considered less similar. Semantic similarity methods 
such as simGIC measure the similarity of sets of terms in ontologies 
(Pesquita et al., 2008) and can therefore quantify the similarity of sets of 
phenotype terms annotating human diseases and mouse mutants, thereby 
providing a measure of their phenotypic similarity. It has been demon-
strated however that semantic similarity methods can be biased by data 
availability. For example, the simGIC method tends to identify larger 
sets of terms, sets of terms that are more similar in size, and sets of terms 
from deeper ontology levels, as being more similar (Kulmanov and 
Hoehndorf, 2017). Gene prioritisation methods that use semantic similar-
ity to quantify phenotypic similarity may therefore be biased by the 
numbers of phenotype terms annotating human diseases and model or-
ganism mutants, which may reflect how well studied these entities are.  
In this study, we demonstrate that whilst disease genes are involved 
in greater numbers of PPIs than non-disease genes in some PPI data-
bases, this may be at least partly a result of them being better studied. 
Scoring genes with more available data more highly may reduce the 
ability of a method to prioritise less-well-studied genes, for which fewer 
data are likely to be available. We therefore develop PhenoRank, which 
uses PPI and phenotype data from multiple species to prioritise disease 
genes, whilst avoiding being biased by the number of data associated 
with each gene. Bias is avoided by comparing gene scores generated for 
the query disease against gene scores generated using simulated sets of 
phenotype terms. Using this simulation-based approach ensures Pheno-
Rank is not biased towards genes with more available data and improves 
its performance. 
2 Methods 
2.1 PPI data 
PPI data were downloaded from four databases: BioGRID (version 
3.4.131) (Chatr-Aryamontri et al., 2015), HI-II-14 (on 27 November 
2015) (Rolland et al., 2014), HPRD (on 30 March 2015) (Keshava 
Prasad et al., 2009) and IntAct (on 4 January 2016) (Orchard et al., 
2014). Only direct interactions, associations and physical associations 
were obtained from BioGRID and IntAct. Duplicate interactions, looping 
interactions and interactions that did not occur between two H. sapiens 
proteins were excluded. Some PPI resources do not record interactions 
between different protein isoforms and we therefore considered all inter-
actions at the gene level. Combined data from the four resources, con-
taining 210,914 unique interactions spanning 16,184 genes, were used in 
PhenoRank (Supplementary Table 1).  
 
2.2 Human disease variant data 
Data downloaded from ClinVar (on 22 October 2016), OMIM (on 1 
November 2016) and UniProtKB (on 22 October 2016) were used to 
define the disease-gene associations used in PhenoRank. ClinVar vari-
ants not marked as pathogenic or likely pathogenic, or whose review 
status was less than two stars were excluded. Non-disease variants from 
UniProtKB were excluded. Disease-gene associations from OMIM were 
not considered if the molecular basis of the disease is unknown. Diseases 
reported using vocabularies other than OMIM were mapped to OMIM 
terms using the cross-referencing provided by the Disease Ontology 
(DO) (Kibbe et al., 2015).  Using these data, we define a disease as being 
associated with a gene if a gene variant is reported as being disease caus-
ing. The combined data set contains 5,685 unique associations between 
4,729 diseases and 3,713 genes (Supplementary Table 2).  
 
2.3 Mouse phenotype data 
Genotypes and phenotype term annotations for 24,834 mouse mutants 
and human-mouse gene orthology data were downloaded from the 
Mouse Genomics Database (MGD, on 13 October 2016). Human 
orthologs of the mutated gene in 21,143 mouse mutants were identified 
using the orthology data. 
 
2.4 Annotating diseases with phenotype terms 
Mappings between disease terms (from OMIM) and phenotype terms 
(from HPO and MP) from HPO (Köhler et al., 2014) and Hoehndorf et 
al. (Hoehndorf et al., 2015) are used in PhenoRank to measure the phe-
notypic similarity of the query disease and diseases in OMIM. 
Hoehndorf et al. mapped phenotype terms (from HPO and MP) to dis-
ease terms (from DO) through automated text mining. Hoehndorf et al. 
determined that the 21 phenotype terms most strongly associated with 
each disease were most informative when quantifying phenotypic simi-
larity and we therefore include these phenotype term mappings in Phe-
noRank. The cross-referencing provided by the DO was used to transfer 
the mapped phenotype terms to the corresponding OMIM diseases. The 
combined data set contains 128,695 unique mappings between 7,042 
OMIM diseases and 8,313 unique HPO and MP phenotype terms (Sup-
plementary Table 3). 
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2.5 Measuring phenotypic similarity  
PhenoRank uses the simGIC similarity measure to compute the pheno-
typic similarity of human diseases and mouse mutants (Supplementary  
Figure 1). Let Wi and Wj be two sets of phenotype ontology terms. In our 
case, these phenotype terms are terms from the HPO or MP that either 
annotate a disease or describe abnormalities observed in a mouse mutant 
(Supplementary Figure 2). Uberpheno, a cross-species ontology gener-
ated by integrating multiple phenotype ontologies, including the HPO 
and MP, is used to compare sets of terms (Köhler et al., 2013). The true 
path rule states that association with an ontology term implies associa-
tion with all ancestors of the term (Pesquita et al., 2008), and we there-
fore add the ancestors of each term in Wi and Wj to the respective set 
using Uberpheno. Each term in Uberpheno is weighted by its infor-
mation content (IC), defined as the negative logarithm of the probability 
that a given disease or mouse mutant is annotated with the term. Using 
simGIC, the similarity S of Wi and Wj is the Jaccard similarity coefficient 
weighted by the IC of each term:  𝑆 𝑊#,𝑊% = 𝐼𝐶(𝑥),∈./∩.1 𝐼𝐶(𝑦)3∈./∪.1 	 
 
2.6 Disease gene prioritisation using PhenoRank 
Let D be the diseases represented in ClinVar, OMIM and UniProtKB, M 
be the mouse mutants reported in the MGD, q be the query disease so 
that qÎD, and Wi be the set of phenotype terms mapped to phenotype 
data source i, which can be either a human disease or mouse mutant. In 
PhenoRank, all diseases in D and mouse mutants in M are first scored by 
their phenotypic similarity to query disease q (Figure 1A). Phenotypic 
similarity is measured by comparing the ontological similarity of the set 
of phenotype terms mapped to q, to the sets of phenotype terms mapped 
to each disease in D and mouse mutant in M, using the simGIC method.  
Diseases and mouse mutants are therefore scored as being phenotypical-
ly similar to q if they are mapped to phenotype terms that are closely 
related in Uberpheno.  
These phenotypic similarity scores are used to score each gene in a 
PPI network. Let G=(V,E) be this network, with V being nodes represent-
ing genes and E being edges representing physical interactions between 
the protein products of the genes. Gene scores are computed using dis-
ease-gene associations from ClinVar, OMIM and UniProtKB, and hu-
man-mouse orthology data from the MGD (Figure 1B). The score of 
gene i is defined as the sum of the phenotypic similarity of each associ-
ated disease and each mutant of an orthologous mouse gene, to q, divid-
ed by the numbers of associated diseases and mouse mutants:  
 𝑄# = 	 𝑆(𝑊7,𝑊%)%∈8/ |𝑌#| + 	 𝑆(𝑊7,𝑊<)<∈=/ |𝑍#|  
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Figure 1:  PhenoRank overview. (A) Phenotypic similarity of the query disease (q) to each disease in OMIM (D) and each mouse mutant in MGD (M) 
is quantified. Thicker lines represent stronger phenotypic similarities. (B) Phenotypic similarity scores are applied to genes in a PPI network, using 
known disease-gene associations and mouse-human gene orthology data. Darker red nodes represent genes with greater relevance to the disease of 
interest. (C) Phenotypic relevance scores are propagated across a PPI network, so that genes that interact with many high scoring genes are also scored 
highly. (D) Gene scores generated for the query disease are compared against gene scores generated using simulated sets of phenotype terms (S). By 
comparing the score the gene receives for the query disease against the distribution of scores the gene receives for the simulated sets of phenotype 
terms, a P value for each gene is generated. In this illustrative example, the computation of a P value for the gene marked X is shown. While only two 
simulated sets of disease phenotypes are shown, PhenoRank is run with 1,000 simulated sets by default. 
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where Yi is the set of diseases associated with gene i, Zi is the set of 
mutants of mouse genes orthologous to gene i and Wq is the set of pheno-
type terms annotating q. Genes are therefore scored highly if they are 
associated with a disease that is phenotypically similar to q, or if they are 
orthologous to a mouse gene whose mutation produces phenotypic ab-
normalities similar to q.  
These gene scores are next propagated across G using the random 
walk with restart (RWR) method (Figure 1C), as this approach has been 
shown to be effective when prioritising disease genes and variants using 
network data (Köhler et al., 2008; Vanunu et al., 2010). Propagation of 
gene scores ensures that genes that interact with many genes that are 
phenotypically relevant to the query disease are also scored highly.  
To account for the differing availability of data between genes, gene 
scores generated for the query disease are compared against gene scores 
generated using simulated sets of phenotype terms (Figure 1D). Simu-
lated sets of phenotype terms are generated by sampling from phenotype 
terms mapped to the same diseases by HPO and Hoehndorf et al. (Sup-
plementary Figure 3B), to ensure that the simulated sets of terms close-
ly resemble the sets of phenotype terms mapped to real diseases. Sets of 
phenotype terms equal in size to the set of terms mapped to q are simu-
lated. To simulate a set of terms of size |Wq|, a single seed term is first 
sampled from HPO or MP. All phenotype terms in HPO and MP are then 
ranked by the number of times they are mapped to the same disease as 
the seed term, with ties ordered randomly. The seed term is itself includ-
ed in this ranking. If fewer than |Wq| terms are mapped to the same dis-
ease as the seed term, then a new seed term is sampled. The top |Wq| 
ranked terms are used as the simulated set of phenotype terms, ensuring 
that the simulated sets contain terms that are frequently mapped to the 
same disease.  
For each simulated set of phenotype terms, all genes are rescored us-
ing the simulated set of terms in place of the query disease, and these 
scores again propagated across the PPI network. When rescoring genes 
all data are unchanged, ensuring that the effect of data availability on 
each gene score is the same for the query disease and each simulated set 
of phenotype terms. Comparing the gene scores generated using the 
query disease against the gene scores generated using each simulated set 
of phenotype terms therefore allows differences in data availability to be 
negated. An empirical P value is computed for each gene by taking the 
proportion of simulated sets of phenotype terms in which the gene is 
scored higher than when q is considered. These P values represent the 
probability of observing a gene score at least as great as that observed, 
given that the gene is not associated with the query disease. A minimum 
P value of 1/𝑢, where 𝑢	is the number of simulated sets of phenotype 
terms used, is applied to ensure that no P values equal zero. We run 
PhenoRank using 1,000 simulated sets of phenotype terms and use these 
P values to prioritise candidate genes. Through the application of Phe-
noRank to 100 randomly selected diseases, we demonstrate that Pheno-
Rank correctly controls the type-1 error rate (Supplementary Figure 4). 
PhenoRank data is available to download 
(https://github.com/alexjcornish/PhenoRank_Data).  
 
2.7 Propagating scores across PPI networks 
PhenoRank propagates gene scores across network G using the RWR 
method (Supplementary Figure 5) (Köhler et al., 2008). Let n be the 
number of vertices in G, A be the column-normalised adjacency matrix 
of G and Qt be a vector of length n and the distribution of scores across 
vertices at time t. Q0 is the initial distribution of gene scores. The distri-
bution of scores across time points is computed iteratively:  𝑄BCD = 1 − 𝑟 𝐴𝑄B + 	𝑟𝑄H 
where r is the restart probability. To make these scores comparable 
across the query disease and the simulated sets of phenotype terms, a 
fixed number of iterations are completed and scores ranked before Phe-
noRank computes P values. 
 
2.8 Evaluating method bias 
We measured the correlation between the gene scores computed by 
PhenoRank and three published gene prioritisation methods (DADA 
(Erten et al., 2011), EXOMISER (Smedley et al., 2015) and PRINCE 
(Vanunu et al., 2010)) and the numbers of data associated with each 
gene, to determine whether the methods are biased towards genes with 
more available data. PhenoRank was run with and without simulated sets 
of phenotype terms (we refer to these method versions as PhenoRank-
Simulation and PhenoRank-NoSimulation), to establish whether the use 
of these simulated sets of terms affects how biased PhenoRank is. 
EXOMISER prioritises disease genes and variants by combining a gene-
based scoring method, which uses PPI data and phenotype data from 
multiple species, with variant-based pathogenicity prediction. We use the 
gene-level scores produced by EXOMISER when evaluating perfor-
mance and therefore refer to the method as EXOMISER-Walker for 
clarity. Gene scores were generated by applying each method to 200 
diseases, randomly selected from those diseases than can be considered 
by all methods. We considered how five features of the data used by 
each method correlate with the computed gene scores:  
i. Network degree of each gene. 
ii. Number of sources of phenotype data. This is defined as the 
number of human diseases and (if used by the method) model organism 
mutants associated with each gene.  
iii. Number of annotating phenotype terms. This is defined as the 
median number of phenotype terms annotating the sources of phenotype 
data associated with each gene.  
iv. Difference in the number of annotating phenotype terms. This 
is defined as the median absolute difference between the number of 
phenotype terms annotating the query disease, and the numbers of phe-
notype terms annotating each source of phenotype data associated with 
each gene.  
v. Ontology depth of annotating phenotype terms. This is de-
fined as the median of the maximum ontology depth of the phenotype 
terms annotating the sources of phenotype data associated with each 
gene.   
PhenoRank and EXOMISER-Walker both use phenotype terms an-
notating each source of phenotype data to measure phenotypic similarity, 
whilst DADA and PRINCE measure phenotypic similarity using text 
mining. We therefore test all five data features when considering Pheno-
Rank and EXOMISER-Walker, but restrict our analysis to data features 
(i) and (ii) when considering DADA and PRINCE.  
 
2.9 Evaluating method performance 
The performance of each gene prioritisation method was evaluated using 
leave-one-out cross-validation. To ensure that any observed performance 
differences were a result of methodology, rather than the data releases 
used, we ran DADA, EXOMISER-Walker and PRINCE using the same 
disease-gene association data used by PhenoRank. Gene-phenotype 
associations used by EXOMISER-Walker were also updated and the IC 
of each phenotype term recalculated. HPO terms mapped to OMIM 
diseases by the HPO were used as input when running EXOMISER-
Walker. We used our own implementation of the PRINCE algorithm, 
which is available in the PhenoRank package. 
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 Disease genes Non-disease genes  
Database Mean 
n. PPIs 
Median 
n. PPIs 
Mean 
n. PPIs 
Median 
n. PPIs 
Difference 
BioGRID 26.3 10.0 18.5 8.0 P<2.2´10-16 
HI-II-14 5.7 2.0 6.7 2.0 P=0.685 
HPRD 10.7 5.0 7.2 3.0 P<2.2´10-16 
IntAct 18.8 7.0 14.3 6.0 P<2.2´10-16 
 
Leave-one-out cross-validation was completed using a set of 2,708 asso-
ciations between diseases that can be input into all four methods, and 
genes that can be scored by all four methods. In each cross-validation 
trial, an association from this set (between disease Di and gene gj Î Si) 
was masked (i.e. removed from the data used by each method). Each 
method was then run using disease Di as input. All other genes associat-
ed with disease Di (gk Î Si, k ¹ j) and genes not scored by all four meth-
ods were excluded from the results. The score of gene gj relative to the 
scores of the other genes in the results was used to evaluate the perfor-
mance of each method. This process was repeated for each of the 2,708 
disease-gene associations. Receiver operating characteristic (ROC) 
curves and the areas under these curves (AUCs) were computed using 
the pROC R package (Robin et al., 2011).  
 
2.10 Selecting method parameters 
Scores propagated across a network using the RWR algorithm con-
verge on a steady-state distribution (Cowen et al., 2017). To determine 
the number of RWR algorithm iterations required by PhenoRank for 
convergence, we ran PhenoRank using 200 randomly selected OMIM 
terms and calculated the mean absolute difference between the gene 
scores computed using between 1 and 29 iterations, and the gene scores 
computed using 30 iterations, demonstrating that scores converge and 
that the mean absolute change in gene score after 20 iterations is <10-5 
for all tested parameters (Supplementary Figure 6A). We next conduct-
ed leave-one-out cross-validation to select an optimal value for restart 
probability r, using only the 2,977 disease-gene associations reported by 
ClinVar, OMIM or UniProtKB that were not in the set of 2,708 associa-
tions used in performance evaluation. This ensured that parameter selec-
tion and performance evaluation were independent, therefore avoiding 
circularity. PhenoRank performs optimally when r=0.1 (Supplementary 
Table 4) and we therefore ran PhenoRank using 20 iterations and r=0.1. 
We used the same approach to determine the number of RWR algorithm 
iterations required by PRINCE and select optimal values for the two 
PRINCE parameters (α and c). Convergence is achieved by 20 iterations 
(Supplementary Figure 6B) and performance is optimal when α=0.5 
and c=-15 (Supplementary Table 4), and we therefore ran PRINCE 
using these values.  
 
2.11 Disease classes 
A disease class was identified for each OMIM disease using the ontolog-
ical structure of the DO (Supplementary Table 5). Each OMIM disease 
was first mapped to a DO term using the cross references provided by 
the DO. Ancestors of these DO terms at the third level of the DO were 
then identified and these broader disease definitions used as disease 
classes. If an OMIM disease mapped to multiple third-level DO terms, 
then the third-level DO term mapped to the greatest number of OMIM 
diseases was used to classify the disease, to reduce the number of classes 
considered. 
3 Results 
3.1 Study bias in PPI databases 
We analysed the numbers of PPIs involving disease and non-disease 
genes to determine whether disease genes are involved in greater num-
bers of PPIs than non-disease genes, and whether study bias is likely to 
contribute to any differences. PPI data were downloaded from BioGRID, 
HI-II-14, HPRD and IntAct and disease-gene association data were 
obtained from ClinVar, OMIM and UniProtKB. If a gene is reported as 
being disease associated by at least one resource, then it is defined as a 
disease gene. Otherwise it is defined as a non-disease gene.  
BioGRID, HPRD and IntAct contain PPIs curated from the litera-
ture. The proteins screened in the studies contributing to these resources 
depend on the aims of the studies and the generation of these data was 
therefore hypothesis-driven (HD). Conversely, HI-II-14 contains interac-
tions identified in a single unbiased screen of 14,000 proteins (Rolland et 
al., 2014) and the generation of these data was therefore hypothesis-free 
(HF). If disease genes are truly involved in greater numbers of PPIs than 
non-disease genes, we would expect disease genes to be involved in 
greater numbers of PPIs than non-disease genes in data sets generated 
using both HD and HF approaches. However, whilst disease genes are 
involved in greater numbers of PPIs than non-disease genes in each of 
the HD data sets, disease genes are involved in similar numbers of PPIs 
as non-disease genes in the HF data set (Table 1).  
If disease genes are better studied, and better studied genes are in-
volved in greater numbers of PPIs in each of the HD data sets, then study 
bias may at least partially explain why disease genes are involved in 
more interactions than non-disease genes in the HD data sets, but not the 
HF data set. To determine whether disease genes are better studied, we 
used the number of PubMed-indexed publications related to each gene in 
gene2pubmed (NCBI Resource Coordinators, 2016) (downloaded 11 
August 2017) as a measure of how well studied each gene is. Disease 
genes tend to be related to greater numbers of publications (median 59 
publications) than non-disease genes (median 13 publications, P < 2.2 × 
10-16, Wilcoxon rank sum test) indicating that they are better studied. 
Better-studied genes are involved in more PPIs than less-well-studied 
genes in each of the PPI data sets (Table 2), although this difference is 
much greater in the HD data sets than in the HF data set. The fact that 
disease genes tend to be better studied than non-disease genes, and that 
better-studied genes are involved in more PPIs than less-well-studied 
genes in the HD data sets, may partly explain why disease genes are 
observed as being involved in more PPIs than non-disease genes in the 
HD data sets. Study bias may therefore at least partially account for the 
differences in the numbers of PPIs that disease and non-disease genes are 
involved in in the HD data sets. 
Table 1: Numbers of PPIs disease and non-disease genes are involved in. 
Differences tested using a two-sided Mann-Whitney U test. 
 Better-studied 
genes 
Less-well-studied 
genes 
 
Database Mean 
n. PPIs 
Median 
n. PPIs 
Mean 
n. PPIs 
Median 
n. PPIs 
Difference 
BioGRID 37.8 18.0 7.2 3.0 P<2.2´10-16 
HI-II-14 6.8 2.0 6.2 2.0 P=0.013 
HPRD 15.2 8.0 3.4 2.0 P<2.2´10-16 
IntAct 26.4 12.0 6.5 3.0 P<2.2´10-16 
Table 2: Numbers of PPIs better and less-well-studied genes are in-
volved in. Better and less-well-studied genes are defined as those in the 
top and bottom thirds of genes ranked by the number of related publica-
tions in gene2pubmed. Differences tested using a two-sided Mann-
Whitney U test. 
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3.2 Bias in network-based gene prioritisation methods  
We measured the correlations between gene scores computed by Pheno-
Rank and three other prioritisation methods, and features of the data used 
by each method, to determine whether the methods are biased by the 
numbers of data associated with each gene. Gene scores computed by 
DADA, EXOMISER and PRINCE are positively correlated with the 
network degree of each gene and the numbers of associated sources of 
phenotype data (i.e. the number of human diseases and model organism 
mutants associated with each gene), suggesting that these methods score 
genes more highly if they are associated with more data (Table 3). The 
scores computed by PhenoRank-NoSimulation are similarly correlated 
with network degree and the number of associated sources of phenotype 
data, whilst the gene scores computed by PhenoRank-Simulation are less 
strongly correlated with these data features, indicating that the use of 
simulated sets of phenotype terms ensures that PhenoRank is less biased 
by data availability.  
        Gene scores computed by PhenoRank-NoSimulation also correlate 
with the number of phenotype terms annotating the sources of phenotype 
data associated with each gene, and the ontology depth of these pheno-
type terms (Table 3). This suggests that PhenoRank-NoSimulation 
scores genes more highly if the human diseases and mouse mutants 
associated with the gene are annotated with greater numbers of terms 
from phenotype ontologies. Differences between the number of pheno-
type terms annotating the query disease, and the numbers of phenotype 
terms annotating gene-associated human diseases and mouse mutants, do 
not correlate with computed gene scores, suggesting that this data feature 
is not a major source of bias. Gene scores computed by PhenoRank-
Simulation are less strongly correlated with the number of annotating 
phenotype terms and the ontology depth of these terms, indicating that 
the use of simulated sets of phenotype terms reduces bias introduced by 
how well human diseases and mouse mutants are annotated with pheno-
type terms. Despite EXOMISER-Walker also using phenotype terms to 
score genes, the gene scores computed by EXOMISER-Walker are not 
strongly correlated with the numbers of annotating phenotype terms, or 
the ontology depths of these terms, possibly reflecting differences in the 
EXOMISER-Walker and PhenoRank-NoSimulation methodologies.  
 
3.3 Evaluation of method performance 
We used leave-one-out cross-validation to evaluate the performances of 
PhenoRank-Simulation, PhenoRank-NoSimulation, DADA, 
EXOMISER-Walker and PRINCE (Figure 2). Using simulated sets of 
phenotype terms improves the performance of PhenoRank (PhenoRank-
Simulation AUC=0.89, PhenoRank No-Simulation AUC=0.77, P < 2.2 ×  
10-16, two-sided DeLong’s method). Reducing the bias of PhenoRank 
towards genes with more available data therefore also improve its per-
formance. PhenoRank-Simulation outperforms DADA (AUC=0.87, P < 
2.2 × 10-16), EXOMISER-Walker (AUC=0.71, P < 2.2 × 10-16) and 
PRINCE (AUC=0.83, P < 2.2 × 10-16). Whilst DADA is the method with 
overall performance most similar to PhenoRank-Simulation, it performs 
much worse than PhenoRank at higher specificities, with PhenoRank-
Simulation and DADA achieving sensitivities of 87% and 47% at 90% 
specificity respectively. DADA however outperforms PhenoRank-
Simulation at lower specificities, with PhenoRank-Simulation and 
DADA achieving sensitivities of 92% and 98% at 50% specificity re-
spectively. 
The bias of DADA, EXOMISER-Walker and PRINCE towards 
genes with more available data may affect their ability to effectively 
prioritise genes associated with fewer available data. To test this, we 
stratified the cross-validation procedure by the PPI network degree of 
each gene and the number of phenotype data associated with each gene. 
The set of 2,708 disease-gene associations used in method performance 
evaluation was split into five strata based on the degree of the gene in 
each disease-gene association, and five strata based on the number of 
phenotype data associated with the gene in each disease-gene associa-
tion. Cross-validation was then run using each of the strata (Figure 3, 
Supplementary Table 6). Each method uses different data and how the 
disease-gene associations were stratified was therefore not the same for 
each method. DADA, EXOMISER-Walker and PRINCE perform better 
when applied to genes with greater degrees and associated with more 
phenotype data, reflecting their biases towards genes associated with 
greater numbers of data. Whilst the performance of PhenoRank-
NoSimulation is similarly affected by the numbers of associated data, 
PhenoRank-Simulation performs more consistently across the strata, 
demonstrating that the use of simulated sets of phenotype terms reduces 
the effect of data availability on method performance. PhenoRank may 
Data feature PhenoRank-
Simulation 
PhenoRank-
NoSimulation 
DADA EXOMISER PRINCE 
Network degree of each gene -0.04 0.91 0.64 0.46 0.47 
Number of sources of phenotype data -0.03 0.21 0.32 0.18 0.26 
Number of annotating phenotype terms -0.04 0.13 NA 0.01 NA 
Difference in the number of annotating phenotype terms -0.01 -0.03 NA -0.05 NA 
Ontology depth of annotating phenotype terms -0.03 0.18 NA 0.02 NA 
Table 3: Correlations between the gene scores computed by each method and features of the data used by each method. DADA and PRINCE do not 
quantify phenotypic similarity using terms from phenotype ontologies, and therefore correlations involving phenotype terms were not measured for 
these methods. Correlations measured using Spearman’s rank correlation coefficient.  
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Figure 2: Performances of PhenoRank-Simulation, PhenoRank-
NoSimulation, DADA, EXOMISER-Walker and PRINCE in leave-one-
out cross-validation.  
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therefore be especially useful when prioritising genes for which fewer 
data are available. 
Genes associated with diseases of different classes are associated 
with different numbers of data (Supplementary Table 7) possibly re-
flecting how well studied different disease classes are. To determine 
whether the performances of PhenoRank-Simulation, DADA, 
EXOMISER-Walker and PRINCE vary between disease classes, we ran 
the cross-validation procedure using disease-gene associations stratified 
by disease class (Supplementary Figure 7, Supplementary Table 8). 
PhenoRank-Simulation was the best performing method in 20 of the 30 
disease classes, DADA in 3 disease classes, EXOMISER-Walker in 2 
disease classes and PRINCE in 6 disease classes. These performance 
differences may be influenced by the biases exhibited by the methods. 
PhenoRank-Simulation outperforms DADA, EXOMISER-Walker and 
PRINCE in the Monogenic Disease and Integumentary System Disease 
classes (P<0.05), but PRINCE outperforms PhenoRank in the Cancer 
class (P<0.05). This may reflect the fact that the mean degree of genes in 
the PPI network used by PRINCE is higher for genes associated with 
diseases in the Cancer class (69.8), than genes associated with diseases 
in the Monogenic Disease (42.8) and Integumentary System Disease 
(29.6) classes. 
In the data sets used by PhenoRank-Simulation, 3,713 human pro-
tein-coding genes are associated with at least one human disease, 8,607 
with mouse phenotype data and 9,618 with either. To determine whether 
the performance of PhenoRank-Simulation is improved by using data 
from both species, we ran the cross-validation procedure using only 
human disease data and only mouse phenotype data. PhenoRank-
Simulation performs better when using both human and mouse data 
(AUC=0.89), than when using only human data (AUC=0.85, P < 2.2 × 
10-16) and only mouse data (AUC=0.80, P < 2.2 × 10-16) demonstrating 
that PhenoRank successfully integrates data from the two species.   
 
3.4 Application of PhenoRank to genes in loci associated with 
rheumatoid arthritis  
We prioritised likely causal genes in loci identified in a GWAS of rheu-
matoid arthritis (Okada et al., 2014) using PhenoRank. Candidate genes 
in the loci were identified by first selecting single nucleotide polymor-
phisms (SNPs) in linkage disequilibrium with the lead SNP (r2>0.05) in 
European populations (Machiela and Chanock, 2014). Regions spanning 
these SNPs were then defined and all genes whose protein-coding re-
gions at least partially overlap these regions were considered candidates. 
Loci containing a gene already known to be associated with rheumatoid 
arthritis were not considered. PhenoRank was then run using rheumatoid 
arthritis as the input disease and the scores of the genes in these loci 
extracted from the generated results file. Four genes (PADI2, SYT7, 
LGALS1 and PLCL2) in the identified loci were implicated by Pheno-
Rank as being involved in rheumatoid arthritis development (P<0.05, 
after within-locus correction for multiple testing, Supplementary Table 
9). None of these four genes are associated with any human disease in 
the data used by PhenoRank, although inflammatory and autoimmune 
phenotypes have been observed in mutants of their mouse orthologs, 
including “increased susceptibility to experimental autoimmune en-
cephalomyelitis” and “abnormal adaptive immunity” (Supplementary 
Table 9). These genes also interact with genes with immune system 
functions, including CD4 and CD8A (Zhu, Yamane and Paul, 2010). It is 
for these reasons that PhenoRank identifies them as being potential can-
didates. Some of these genes have been previously implicated in auto-
immune disease: PADI2 expression has been demonstrated to correlate 
with arthritis severity in mice (Johnsen et al., 2011), LGALS1 damages 
cartilage via inflammation in osteoarthritis (Toegel et al., 2016) and 
PLCL2 has been associated with systemic sclerosis (Arismendi et al., 
2015).  
4 Conclusions 
It has been suggested that the proteins involved in greater numbers of 
interactions may be less able to tolerate mutations, as a greater propor-
tion of their sequence may be required to facilitate the interactions, 
thereby increasing the likelihood that they are disease-associated (Yates 
and Sternberg, 2013). In this study, we show that whilst the protein 
products of disease genes tend to be involved in greater numbers of PPIs 
in HD data sets, this may be at least partly a result of them being better 
studied. PPI networks generated through high-throughput approaches, 
which are less susceptible to study bias, currently cover only a small 
proportion of the PPIs thought to occur in cells (Rolland et al., 2014). It 
may not be possible to determine whether the number of interactions a 
protein is involved in affects the likelihood of it being disease-associated 
until we have a more comprehensive, accurate and unbiased map of the 
interactome.  
Genes associated with diseases of difference classes tend to be in-
volved in different numbers of PPIs (Supplementary Table 7). In the 
PPI network used by PhenoRank, genes involved in cancer have a mean 
degree of 99.5, whilst genes involved in inherited metabolic disorders 
have a mean degree of only 18.2. The better characterisation of pathways 
involved in cancer may at least partly explain this difference. The differ-
ing performances of PhenoRank, DADA, EXOMISER-Walker and 
PRINCE across disease classes suggests that a user should consider how 
well studied a disease is when selecting a prioritisation method. A meth-
od that performs well when more data are available, such as DADA, 
EXOMISER-Walker or PRINCE, may be more suitable for studying 
diseases with more available data, whilst methods that are less biased by 
data availability, such as PhenoRank, may be more suitable for studying 
diseases with few available data. 
Gillis and Pavlidis (2012) describe study bias in PPI networks in re-
lation to predicting gene function. They suggest that genes involved in 
more interactions may represent highly studied genes, and that these 
genes may be more open to the accumulation of false positive interac-
tions as a result of this. If highly studied genes are involved in more false 
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Figure 3: Method performance when applied to genes with different 
numbers of associated data. For each method, the testing data set of 
2,708 disease-gene associations was stratified based on (A) the network 
degree of each gene and (B) the number of sources of phenotype data 
associated with each gene, and leave-one-out cross-validation 
completed. The size of each circle represents the numbers of disease-
gene associations in the testing data set strata. 
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positive interactions, then this may partially explain why the use of simu-
lated sets of disease phenotype terms improves PhenoRank performance, 
as using this simulation-based approach reduces the score of high-degree 
genes, thereby reducing the influence of interactions that are more likely 
to be false positives. 
The gene scores computed by PhenoRank-NoSimulation, DADA, 
EXOMISER-Walker and PRINCE most strongly correlate with the de-
gree of the genes in the networks used by the methods. This suggests that 
differences in PPI network degree is a major source of bias affecting 
these methods. Whilst DADA adjusts for the degree of candidate genes 
in PPI networks in order to better prioritise genes of low degree, it is still 
biased towards genes of high degree. This is likely because DADA em-
ploys a “uniform scoring strategy”, in which raw and degree-adjusted 
gene scores are combined to produce the final gene ranking. 
While PhenoRank was developed to prioritise genes in disease-
associated loci, the method could be extended to prioritise disease vari-
ants. Methods such as EXOMISER and eXtasy (Sifrim et al., 2013) have 
demonstrated that the integration of a variant effect predictor with gene-
level prioritisation can aid in pathogenic variant identification. The use 
of a method that is less biased towards genes for which more data are 
available, such as PhenoRank, alongside a variant effect predictor may 
allow for the more effective prioritisation of variants in genes that are 
less well studied.   
Whilst existing network-based gene prioritisation methods are bi-
ased toward genes for which more data are available, the use of simulat-
ed sets of phenotype terms ensures that PhenoRank is not similarly bi-
ased. Although high-throughput phenotypic screens are being completed 
(Brown and Moore, 2012), many data sources are still likely to be influ-
enced by study bias. Approaches similar to the simulated sets of pheno-
type terms used by PhenoRank could be incorporated into existing priori-
tisation methods, such as DADA, PRINCE and EXOMISER, to reduce 
the influence of study bias.		
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